NCT01194037View on ClinicalTrials.gov

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 23, 2011

Primary Completion Date

November 28, 2011

Study Completion Date

November 28, 2011

Conditions
Chronic Hepatitis C InfectionGenotype 1
Interventions
DRUG

recombinant variant of interferon-alpha 2b

SC, Weekly

DRUG

Peginterferon alfa-2a

SC Weekly

DRUG

Ribavirin

Oral administration (The daily dose of ribavirin(RBV) was 1000mg for subjects weighing \< 75 kg or 1200 mg for subjects weighing ≥ 75 kg)

Trial Locations (6)

90036

Los Angeles

Unknown

National City

Miami

Atlanta

Lexington

New Orleans

Sponsors
All Listed Sponsors
lead

HanAll BioPharma Co., Ltd.

INDUSTRY

NCT01194037 - A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C | Biotech Hunter | Biotech Hunter